Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Septerna, Inc. (SEPN)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced today that on February 6, 2026, the company’s Board of Directors granted an inducement award to Mark A. Wilson, Septerna’s Chief Legal Officer, consisting of a non-qualified stock option to purchase 165,000 shares of common stock under the Company’s 2026 Inducement Plan. The award was granted as an inducement material to Mr. Wilson’s employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $25.41 per share, equal to Septerna’s closing share price on February 6, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the remaining 75% vesting thereafter in equal monthly installments over 36 months, subject to Mr. Wilson’s cont
Show less
Read more
Impact Snapshot
Event Time:
SEPN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SEPN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SEPN alerts
High impacting Septerna, Inc. news events
Weekly update
A roundup of the hottest topics
SEPN
News
- Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual MeetingGlobeNewswire
- Septerna (NASDAQ:SEPN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Septerna (NASDAQ:SEPN) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Septerna (NASDAQ:SEPN) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SEPN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a>MarketBeat
- Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer [Yahoo! Finance]Yahoo! Finance
SEPN
Sec Filings
- 2/10/26 - Form 4
- 2/10/26 - Form 4
- 2/10/26 - Form 4
- SEPN's page on the SEC website